Petros Grivas, MD, PhD, discusses the utility of enfortumab vedotin-ejfv in the second- and third-line setting for patients with urothelial carcinoma.
Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington (UW) School of Medicine, clinical director, Genitourinary Cancers Program, UW Medicine, associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the utility of enfortumab vedotin-ejfv (Padcev) in the second- and third-line setting for patients with urothelial carcinoma.
Enfortumab vedotin is indicated for use in the second-line setting for patients who are not eligible for cisplatin, and for those who received first-line treatment with chemotherapy or a checkpoint inhibitor, according to Grivas. This is based on data from cohort 2 of the phase 2 EV-201 trial (NCT03219333), in which the agent demonstrated a response rate of 52% in 89 patients with this disease, Grivas says.
In the third-line setting, results from the phase 3 EV-301 trial (NCT03474107) demonstrated that the agent had level 1 evidence of significant overall survival and progression-free survival benefit. The agent also produced higher response rates vs chemotherapy in this population, Grivas explains. This evidence confirms the utility of enfortumab vedotin in the third-line setting for patients who were previously treated with chemotherapy and immunotherapy, Grivas concludes.